App-Quantinova.ai

The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer

Elgene Lim - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Androgen Tear

Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database

Hongchao Pan - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

Miguel Martn - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Capecitabine

AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

Luc Dirix - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

EDP 202

TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC)

Hope S Rugo - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

IMMU132

TRYbeCA-2: A randomized phase 2/3 study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer (NCT03674242)

Ahmad Awada - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Carboplatin

A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

Dejan Juric - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)

Peter Kaufmann - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Eribulin

Association of cardiac energetics and plasma biomarkers with anthracycline-based chemotherapy in breast cancer patients

Olga Oikonomidou - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Assessing immune biomarkers of response to anthracyclines in breast cancer

Melanie Spears - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

cGAS-STING driven immune activation predicts response to neoadjuvant chemotherapy and suggests rational IO combination therapies: Results of the Neo-DDIR study

Stuart A McIntosh - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data

Olga Oikonomidou - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cardiotoxicity

Epirubicin

Prevention of shoulder problems trial (UK-PROSPER): Exercise to prevent shoulder problems in patients undergoing breast cancer treatment

Julie Bruce - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

How patient advocates and researchers work together in PRECISION* to identify low-risk ductal carcinoma in situ (DCIS) that may not need aggressive treatment

Deborah Collyar - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study

Sherko Kmmel - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Hyaluronidase

Targetable ERBB2 mutations independently predict an aggressive phenotype in primary, ERBB2 non-amplified, hormone receptor positive lobular breast cancer

Sasagu Kurozumi - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Neratinib

Can some ER+/HER2+ patients be safely spared from treatment with chemotherapy plus herceptin?

Arran K Turnbull - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Trastuzumab

Cardiac events in patients with HER2-positive metastatic breast cancer who have low left ventricular ejection fraction prior to initiating treatment with ado-trastuzumab emtansine: A retrospective cohort study using electronic health record data

Thibaut Sanglier - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab emtansine

Use of pertuzumab in combination with taxanes for HER2+ metastatic breast cancer: Analysis of U.S. electronic health records

Letizia Polito - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Pertuzumab

Neratinib reduces HER2+/luminal B breast cancer stem cell activity and inhibits resistance by blocking efflux mechanisms

Nathan Hull - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Mitoxantrone

Filters

45280 Abstracts